It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
To illustrate the surgical technique and explore clinical outcomes of the reconstruction for the malignant and metastatic bone tumour of proximal femur with metallic modular intercalary prosthesis. Sixteen patients who underwent modular intercalary prosthetic reconstruction after tumour resection were included from April 2012 and October 2020. Prosthesis and screws parameters, resected bone length and residual bone length, clinical outcomes and survivorship were analyzed. All patients were followed up for an average of 19 months (range 1–74). In our series, 12 patients died of the progression of the primary disease at the final follow-up. The cumulative survivorship since the treatment of proximal femoral metastasis was 78.6% (11 patients) at 6 months and 38.5% (5 patients) at 1 year. The mean MSTS score was 22.25 ± 4.55 among all patients. There were no cases of loosening or breakage of the prostheses, plates or screws, despite the various measurements of prostheses and residual bones. Modular intercalary prosthetic reconstruction was an effective method for malignant tumour of the proximal femur, including the advantages of providing early pain relief, quickly restoring postoperative function, required a short operation time, and preserving the adjacent joints.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Tianjin Medical University, Graduate School, Tianjin, China (GRID:grid.265021.2) (ISNI:0000 0000 9792 1228); Xing’anmeng People’s Hospital, Ulanhot, China (GRID:grid.265021.2)
2 Xing’anmeng People’s Hospital, Ulanhot, China (GRID:grid.265021.2)
3 Binzhou Medical University Hospital, Binzhou, China (GRID:grid.440653.0) (ISNI:0000 0000 9588 091X)
4 Tianjin Medical University, Graduate School, Tianjin, China (GRID:grid.265021.2) (ISNI:0000 0000 9792 1228)
5 Beijing Jishuitan Hospital Guizhou Hospital, Guiyang, China (GRID:grid.414360.4) (ISNI:0000 0004 0605 7104)
6 Tianjin Hospital, Department of Bone Tumor and Soft Tissue Oncology, Tianjin, China (GRID:grid.417028.8) (ISNI:0000 0004 1799 2608)